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Aims & Objective: 
 
1. To estimate and compare salivary and blood glucose level in diabetic (controlled and   
uncontrolled) and non diabetic patients. 
 
2. To estimate and compare salivary and blood AGE level in diabetic (controlled and 
uncontrolled) and non diabetic patients. 
 
3. Assess the periodontal status of diabetic (controlled and uncontrolled)  and 
non diabetic patients and its correlation to salivary glucose and salivary AGE levels. 
 
Hypothesis 
1.  There is increase in salivary and serum AGE level in diabetic patients compared 
      to non diabetic patients. 
 
2.  Salivary AGE level is directly proportional to blood AGE level. 
 
3. Increase in salivary glucose and salivary AGE level is associated with poor periodontal 
    status in diabetic  patients 
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STUDY SETTING 
           Diabetic patients attending (n = 50) the Department of Diabetology, Voluntary 
Health service (VHS), Chennai and non-diabetic controls (n = 25) attending the 
department of Oral and Maxillofacial Pathology, Ragas Dental College & Hospital 
were included in the study. Verbal consent was obtained from every individual 
participating in the study .The study was approved by Institutional Review Board. 
      The patient were divided into three groups 
 
GROUP 1: (n = 25) 
Comprised of controlled diabetic patients of 40-60 years of age. Controlled diabetes 
was defined as those having random non-fasting plasma glucose values >120 mg/dl 
and < 200mg/dl (controlled diabetics) 
 
GROUP 2: (n = 25) 
Comprised uncontrolled diabetic patients of 40-60 years of age. Uncontrolled 
diabetes was defined as those having random non fasting plasma glucose values 
>200mg/dl (uncontrolled diabetics) 
 
GROUP 3: (n = 25) 
 Comprised of non -diabetic patients whose age and sex were matched with Group I 
and Group II with random non fasting plasma glucose values <120mg/dl (non-
diabetics) 
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EXCLUSION CRITERIA 
 Patient with removable partial or complete dentures. 
 Patients who had taken antibiotics or antifungal medication for any condition for a 
period of 15 days before the sample collection. 
 Patients with immunocompromised condition other than Diabetes mellitus 
 Pregnant women 
 Patients who had the habit of tobacco/areca nut use 
MATERIALS (figure 1 and 2) 
 Test tubes 
 Tourniquet 
 Sterile disposable syringes 
 Mouth mirror 
 Explorer 
 Light source 
 Eppendof tubes 
 Saliva spitting container  
 Ice flask 
 Cotton 
 Spirit 
 CPITN (Community Periodontal Index for Treatment Needs) 
 EDTA (Ethylene diamine tetraacetic acid) 
 Fluoride 
 NMR tubes 
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 NMR tube holder 
 Acetone 
 Pipette 
REAGENTS AND CHEMICALS (Figure 3) 
1. Glucose estimation kit: Glucose oxidase method 
Contents of the reagent: 
1000 ml Enzyme reagent 
Phosphate buffer (ph 7.5)     0.1mmol/l 
4-Aminophenazone              0.25mmol/l 
Phenol                                  0.75mmol/l 
Glucose oxidase                   >15KU/l 
Peroxidase                            >1.5KU/l 
Mutarotase                           >2.0KU/l 
Stabilizers 
3ml standard 
Glucose                               100mg/dl or 5.5mmol/l 
2. Glycosylated hemoglobin kit:  Ion-exchange resin method (figure 4) 
Contents of the reagent: 
Ion exchange resin       25x3ml 
(Predispensed Tubes) 
Lysing reagent              2.5ml 
Control (10%GHb)      1x1ml 
Resin separators           25nos 
 8
3, Nuclear magnetic resonance spectroscopy 
    Deuterium oxide 99 atom % 
EQUIPMENTS (figure 5, 6, and 7) 
 Autoclave 
 Semi-automated analyzer 
 Refrigerator 
 500 MHz Nuclear magnetic resonance spectroscopy 
 NMR sample mixer 
 NMR software 
PROCEDURE 
1.    History 
          A detailed case history was taken for all patients which included their habits, 
          medication and  oral hygiene habits 
2.    Collection of blood sample 
         2ml of venous blood was drawn from the brachial vein for estimation of blood 
         glucose and glycosylated hemoglobin levels. 
3.      Estimation of blood and salivary glucose level done by glucose oxidase method 
4.      Estimation of glycoslated hemoglobin was done using ion-exchange resin    
         method 
5.     Collection of unstimulated saliva sample - Spit technique 
        Patient was asked to sit in the dental chair with head tilted in front and 
         instructed not to speak/swallow or do any head movements during the procedure 
         In the beginning the patient was asked to swallow any saliva if present in the 
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         mouth .After this the patient was instructed to spit in a sterile graduated    
         container 
6.    Glucose levels of unstimulated saliva were estimated using glucose oxidase    
         method in a semi-automated analyzer. The glucose standard was diluted ten    
         times for estimation of salivary glucose levels. 
LABORATORY METHODS: 
1. Estimation of blood and salivary glucose: 
                  100µl of saliva and 0.2ml of blood samples were mixed with the reagent in the     
          ratio of 1:3 and incubated for 5 minute at 37 C. The absorbance of standard and the 
          samples against the reagent blank were measured. For salivary glucose estimation 
          100mg glucose standard which is usually used for blood glucose estimation was 
          diluted at 1: 10 ml to a final concentration of 10mg/dl 
         Principles: 
                 The glucose is determined after enzymatic oxidation in the presence of glucose    
         oxidase (GOD). Hydrogen peroxide that is formed is catalysed by peroxidase    
         (POD) and reacts with phenol and 4-aminophenazone to give a red – violet colour    
         that is indicative of the quinoneimine dye. The amount of coloured complex    
         formed is proportional to the glucose concentration and can be photometrically    
         measured. 
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       Glucose + O2 + H2O      Gluconic acid + H2O2 
                                                                                                              POD 
         2 H2O2    + 4- aminophenazone + phenol  Qunoneimine + 4 H2O 
2. Estimation of glycosylated hemoglobin in blood: 
A. Hemolysated preparation: 
     1. Dispense 0.5ml lysing reagent into tubes labeled into tubes labeled as 
         control (C) and test (T). 
    2. Add 0.1ml of the reconstituted control and well mixed blood sample into the 
  appropriately labeled tubes. Mix until complete lysis is evident. 
    3. Allow to stand for 5 minutes. 
    B. Glycosylated hemogobulin (GHb) separation: 
    1.   Remove cap from Ion –exchange resin tubes and label as control and sample. 
2. Add 0.1ml of the hemolysate from step A into the appropriately labeled Ion 
exchange resin tubes 
3. Insert a resin separator into each tube so that the rubber sleeve is approximately 1 
cm above the level of the resin suspension. 
4. Mix the tubes on a mixer continuously for 5 minutes. 
5. Allow the resin to settle, push the resin separator into the tubes until the resin is 
firmly packed. 
    6.  Pour or aspirate such supernatant directly into the cuvette and measure each 
  absorbance against distilled water 
 
GOD 
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    Total Hemoglobin (THb) fraction: 
    1. Dispense 5ml of distilled water into the tubes labeled as control and sample 
    2. Add to it 0.02 ml of hemolysate from step A into appropriately labeled 
  tube. Mix well 
   3. Read each absorbance against distilled water. 
       Calculations: 
         Ratio of control (Rc)      =     Abs. Control GHb 
                                                       Abs. Control THb 
         Ratio of sample (Rs)      =     Abs. Sample GHb 
                                                       Abs. Sample THb 
        Using the conversion chart in (Annexure 2) HbA1c % is obtained from total   
        glycosylated  hemoglobin (GHbA1) 
  3. Estimation of Salivary AGE level using NMR 7 
    To quantitate AGE concentration, proton-NMR (1H-NMR) measurements were 
    carried using a Jeol ECA 500 FT spectrometer (Jeol Japan) ® operating field strength 
    of 500 MHz. Sample were made with 0.1ml of saliva mixed with 0.6ml of D2O 
    (99.95% purity,fisher scientific) and mixed thoroughly by vortex for 3 minutes at 
    room temperature. The sample was poured into a Wilmad precision glass® NMR test 
    tube with an inner diameter of 5mm.All spectra were recorded at a controlled probe 
    temperature of 21/25◦C The spectra processing was carried out using Jeol Delta 
    software®.  The signal from deuterium oxide was used to optimize the homogeneity of 
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    the magnetic field, and the fine adjustment was done by inspection of the free – 
   induction decay obtained without water suppression. A field frequency was provided 
   by detecting the deuterium signal of deuterium oxide. The proton spectra were 
   obtained by using a flip angle of 90 degree. Pulse conditions were 128 accumulations.    
   The relative intensity of the resonance of AGEs were determined by comparison with    
   the intensity of the resonance of D2O.Resonance intensity can be used to determine  
   concentration, provided that the line widths are comparable. Peak height can be used to  
   determine concentrations, provided that the line widths are comparable. Using the  
   internal references, concentrations were calculated from the peak heights of identified  
   substances which revealed a linear  relationship between concentration and peak height.  
   Therefore, the resonance intensity of the respective substance was used for  
   quantification. 
Assessment of periodontal status 8  (Figure 8) 
Clinical attachment loss / attachement level was the criteria used to determine the 
periodontal status of individual teeth.  Clinical attachment loss is the distance between the 
base of the pocket and a fixed point on the tooth such as cementoenamel junction. A 
manual CPITN probe was used to determine the pocket depth. The pocket depth was 
measured on six sites of the all the teeth present. The surfaces probed were mesio 
buccal/labial, mid-Buccal /labial, disto- buccal / labial, mesio-lingual / palatal, mid-
lingual / palatal, disto-Lingual / palatal and the scores were recorded in the appropriate 
box in the chart (Annexure I).The measurements were taken when a slight resistance to 
the probe penetration was felt and care was taken to assure that all the measurements 
were made with the probe tip parallel to the tooth axis.  
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Determining the level of attachment: 
    When the gingival margin is located on the anatomic crown, the level of attachment is 
determined by subtracting the distance from the gingival margin to the CEJ from the 
depth of the pocket. If both are the same, the loss of attachment is zero. 
     When the gingival margin coincides with the CEJ, the loss of attachment equals the 
pocket depth. 
     When the gingival margin is located apical to the CEJ, the loss of attachment is 
greater than the pocket depth, and therefore the distance between the CEJ and gingival 
margin should be added to the pocket depth.  
All the teeth with probing depth ≥ 4mm or clinical attachment loss of ≥ 1mm was 
considered as involved with periodontal disease. The total number of teeth with 
periodontal diseases was counted. The number of teeth in the oral cavity was counted and 
a percentage was derived to determine whether the disease was localized or generalized. 
if less than thirty percent of teeth were involved it was considered as localized 
periodontitis and more than thirty percent was considered as generalized periodontitis.  
Codes: 
 
Code – 0 – no periodontal disease (Healthy periodontium) 
 
Code – 1 – Bleeding observed during or after probing 
 
Code – 2 – Calculus or other plaque, retentive factors either seen or felt during probing 
 
Code – 3 – Pathological pocket 4 to 5 mm in depth 
    
                  Gingival margin situated on the black band of  the probe 
 
Code – 4 - Pathological pocket of 6mm or more in depth, black band of the probe not        
                  visible. 
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           Data entry, database management and all statistical calculations were performed 
with the aid of the Statistical Package for the Social Sciences (SPSS, version 11.5) 
software. Descriptive statistics were calculated for all variables. Differences in means 
between more than two groups were assessed using the one way (ANOVA) and post hoc 
analysis using Tukey’s test. Relationships between variables were evaluated by Pearson’s 
correlation coefficient. Linear regression line was drawn to find the scatterness of the 
points between random blood glucose and HbA1C, random blood glucose and salivary 
glucose, random blood glucose and salivary AGE, salivary AGE and HbA1C, salivary 
glucose and salivary AGE levels, salivary glucose and periodontal status, salivary AGE 
and periodontal status. A p value of <0.05 was considered to be statistically significant. 
When the observed value of the correlation coefficient did not show statistical 
significance, the result was considered as a non – linear relationship.  
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INTRODUCTION REVIEW 
 
HISTORY (2004) 4 
 
      The word Diabetes was first used by Aretaeus of Cappadocia in the 2nd century     
       AD. It comes from the Greek, meaning siphon (because the fluid does not remain  
       in the body, but uses the man’s body as a channel whereby to leave it. Aretaeus      
       gave a clinical description of the disease, noting the increased flow, thirst and    
       weight loss.The sweet, honey taste of urine in polyuric states, which attracted ants    
       and   insects, was reported by Hindu physicians such as (Susruta) during the 5th    
       and 6thcentury AD. John Rollo (d.1809) was the first to apply the adjective   
       Mellitus to the diasease. 19th century Claude Bernard (1813-1878) discovered that   
       sugar appeared in  urine was stored in the liver.Oskar Minkowski and Joseph Von   
       Mering (1849-1908) showed pancreatic disorder causes diabetes.Paul Langerhans   
      (1847-1888) was the first to describe the clusters of cells in the pancreas and 
named it as islets of langerhans and suggested that they were endocrine tissues of 
the pancreas that produced a glucose –lowering hormone.Insulin was discovered 
in 1921 at the university of Toronto, Canada by Frederick et al .By 1950 it was 
accepted that tissue complications, such as occur in the eye and kidney continued 
to develop in long standing diabetes in spite of insulin treatment. 
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DEFINITION 
         Diabetes mellitus by (WHO) is a condition in which the pancreas no longer 
produces enough insulin or when cells stop responding to the insulin that is produced, 
so that glucose in the blood cannot be absorbed into the cells of the body. Symptoms 
include frequent urination, lethargy, excessive thirst, and hunger. The treatment 
includes changes in diet, oral medications, and in some cases, daily injections of 
insulin4 
  CLASSIFICATION OF DIABETES (2004) 9 
1. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin     
    deficiency) IDDM 
      a.   Immune-mediated diabetes. - Previously encompassed by the terms   insulin-    
dependent diabetes, type I diabetes, or juvenile-onset diabetes, results from a cellular-
mediated autoimmune destruction of the β-cells of the pancreas. Seen in Graves’ 
disease, Hashimoto's thyroiditis, Addison's disease, vitiligo, celiac sprue, autoimmune 
hepatitis, myasthenia gravis, and pernicious anemia. 
      b. Idiopathic diabetes - These patients have permanent insulinopenia and are 
prone to ketoacidosis, but have no evidence of autoimmunity. Individuals with this 
form of diabetes suffer from episodic ketoacidosis 
2. Type 2 diabetes (NIDDM) 
 Ranges from predominantly insulin – resistant, with relative insulin deficiency, to 
predominantly insulin- secretory defect, with or without insulin resistance 
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3. Other specific types  
a. Genetic defects of β-cell function 
  Chromosome 12,HNF-1α(formerly MODY-3)(maturity- onset diabetes of  the young 
  Chromosome 7, glycokinase (formerly MODY-2) 
  Chromosome 20, HNF-4α (formerly MODY-1) 
  Mitochondrial DNA 
  Insulinopathies 
B. Genetic defects of insulin action 
  1. Type A insulin resistance                3. Rabson-Mendenhall syndrome 
  2. Leprechaunism                                4. Lipoatrophic diabetes 
C. Diseases of the exocrine pancreas 
  1.  Pancreatitis                                    4. Cystic fibrosis 
  2. Trauma/pancreatectomy                 5. Haemochromatosis 
  3.  Neoplasia                                       6. Fibrocalculous pancreatopathy 
D. Endocrinopathies 
  1. Acromegaly                                     5. Hyperthyroidism 
  2. Cushing’s syndrome                       6. Somatostatinoma 
  18
  3. Glucagonoma                                  7. Aldostatinoma 
 4. Plaeochromocytoma 
  E. Drug induced 
 1. Glucocorticoids                                6. Thyroid hormone 
 2. Thiazides                                          7. Diazoxide 
 3. Vacor                                                8. Dilantin 
 4. Pentamidine                                     9. Interfron – α 
5. Nicotinic acid 
  F. Infections 
 1. Congenital rubella 
 2. Cytomegalovirus 
G. Other genetic syndromes sometimes associated with diabetes 
 1.  Down’s syndrome                           4. Wolfram’s syndrome 
 2. Klinefelter’s syndrome                    5.Huntington’s syndrome 
 3. Turner’s syndrome 
 4. Gestational diabetes 
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DIAGNOSTIC CRITERIA FOR DIABETES (2008) 9 
 Diagnosis of diabetes and impaired glucose homeostasis, ADA guidelines 
(Standards of medical care in diabetes, 2007) 
Fasting glucose 
Normal                                                     <100mg/dl 
Prediabetes: impaired fasting glucose     100-125mg/dl 
Diabetes                                                   >126mg/dl 
 
(oGTT) or random glucose 
Normal                                                       <140mg/dl 
Prediabetes: impaired glucose tolerance   140-199mg/dl 
Diabetes                                                     >200mg/dl 
Glycoslyated hemogloblin 
Normal                                                      <7 % 
Diabetes                                                     >7 % 
TESTING OF GESTATIONAL DIABETES (GMD) 9 
Pregnant women who fulfill all of these criteria need not be screened for GDM.  
This low-risk group comprises women who  
• are <25 years of age 
• are a normal body weight 
• have no family history (i.e., first-degree relative) of diabetes 
• have no history of abnormal glucose metabolism 
• have no history of poor obstetric outcome 
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Role of glycosylated hemoglobin (A1C) level as a criterion for the diagnosis of 
diabetes  
Soon after the introduction of the glycosylated hemoglobin assay as an index of 
glycemia, its use for the diagnosis of diabetes was considered. Measurement of 
glycohemoglobin (A1C) for this purpose has numerous advantages. 
1) A1C measures average glycemic levels in a time scale of weeks, whereas plasma 
glucose varies greatly within any given day and from day to day. Thus, an elevated 
A1C indicates a chronic state of hyperglycemia. 
2) The patient does not have to fast or otherwise prepare, and a blood sample can be 
drawn any time of day.  
3) In reference laboratories, the precision of A1C measurement is similar to the 
measurement of plasma glucose  
4) A test that can be used to diagnose diabetes and evaluate the results of treatment is 
an attractive measurement, as compared with our current situation, which calls for 
using different tests to diagnose the disease and then monitor treatment.  
5) There is a threshold level of A1C associated with risk for retinopathy. 
6) A1C assays had a mean sensitivity of 66% and a specificity of 98%. 
Disadvantages. 
1, Procedure not standardized all countries 
2, A1C values may be affected by other conditions (e.g,hemoglobinopathy,       
pregnancy, uremia, blood transfusion, and hemolytic anemia) 
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3, A chemical preparation to create uniform calibration standards has only recently 
been established 
DIABETES CONTROL AND ITS MEASUREMENT 4 
                         INDEX               MAIN CLINICAL USE 
Urine glucose Only crude index of BG (blood glucose), 
last resort in type 2 diabetes 
Blood glucose 
A, Fasting 
 
B, diurnal/circadian profiles                         
 
 
Correlated with mean daily BG and 
HbA1C in type 2 diabetes 
Self monitoring of BG, hospital 
assessment 
Glycated hemoglobin Glycaemic control (mean) over preceding 
1-3 months 
Glycated serum protein eg fructosamine Glycaemic control (mean) over preceding 
2 weeks 
Urine ketones Insulin deficiency, warning of DKA 
(diabetic ketoacidosis) 
Other blood metabolites/hormones 
A, Cholesterol 
B, Triglyceride 
 
Cardiovascular risk factor  
Cardiovascular risk factor 
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PATHOPHYSIOLOGY OF DIABETES (2003) 10 
I. Type 1 (previously called insulin dependent diabetes mellitus (IDDM) or 
juvenile-onset diabetes) 
A. Causes 
1. Genetic predisposition. 
2. Environmental exposure: virus, toxin, stress. 
3. Autoimmune reaction: beta-cells that produce insulin in the pancreas are destroyed. 
   When 80-90% of the beta-cells are destroyed, overt symptoms occur. 
B. Characteristics 
1. Usually occurs before 30 years of age, but can occur at any age. Peak incidence 
   occurs during puberty, around 10-12 years of age in girls and 12-14 years in boys. 
2. Abrupt onset of signs and symptoms of hyperglycemia: increased thirst and hunger, 
   frequent urination, weight loss, and fatigue. 
3. Ketosis prone. 
II. Type 2 (previously called non-insulin dependent diabetes mellitus, NIDDM, or 
adult-onset diabetes) 
A. Causes 
1. Insulin resistance: unable to utilize insulin that the body makes because of cell-   
    receptor defect; glucose is unable to be absorbed into cells for fuel. 
2. Decreased insulin secretion: pancreas does not secrete enough insulin in response  
    to glucose levels. 
3. Excess production of glucose from the liver: result of defective insulin secretory  
    response. 
B. Characteristics 
1. Usually occurs after 30 years of age, but is now occurring in children and     
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    adolescents. 
2. Increased prevalence in some ethnic groups, e.g., African Americans,   
    Hispanic/Latino, Native Americans, Asian Americans, and Pacific Islanders. 
3. Strong genetic predisposition. 
4. Frequently obese. 
5. Not prone to ketoacidosis until late in course or with prolonged hyperglycemia. 
6. May or may not have symptoms of hyperglycemia. 
7. May also have extreme tiredness, blurred vision, delayed healing, numbness and 
    tingling of hands and feet, recurring yeast infection. 
8. Children between the ages of 10-19 that have one or more of the following are at an 
     increased risk: 
 • Family history 
• Member of certain ethnic populations 
• Overweight 
• Sedentary lifestyle 
 • Pre-puberty. 
• Signs of insulin resistance or conditions associated with insulin resistance 
(acanthosis nigricans [dirty-neck syndrome] Acanthosis Nigricans can help  
identify persons who have high insulin levels and who may be at-risk for developing 
diabetes, hypertension [high blood pressure], dyslipidemia [lipoproteins inbalance], 
polycystic ovarian syndrome[PCOS] 
MECHANISM OF HYPERGLYCEMIA INDUCED DAMAGE (2004)4 
Four major hypotheses about how hyperglycemia causes diabetic complication 
1. Increased influx of glucose and other sugars through the polyol pathway. 
2. Increased intracellular formation of advanced glycation end products (AGE). 
3. Activation of protein kinase C (PKC) isoforms. 
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4. Overactivity of hexasamine pathway. 
POLYOL PATHWAY (2003)11 
Diabetes causes increased oxidative stress in various tissues as evidenced by increased 
levels of oxidized DNA, proteins, and lipids. Besides damaging the functions of these 
molecules, oxidative stress also triggers a series of cellular responses, including the 
activation of protein kinase C (PKC), transcription factor NF- B, and JNK stress-
associated kinases , and so forth. Inappropriate activation of these important 
regulatory molecules would have deleterious effects on cellular functions, and it is 
thought to contribute to the pathogenesis of various diabetic complications. However, 
it is not clear how hyperglycemia leads to increased oxidative stress. It is most likely 
the combined effects of increased levels of reactive oxygen species (ROS) and 
decreased capacity of the cellular antioxidant defense system. Glucose auto-oxidation, 
nonenzymatic glycation, and the interaction between glycated products and their 
receptors , overproduction of ROS by mitochondria , and the polyol pathway , all are 
potential sources of hyperglycemia-induced oxidative stress. 
ADVANCED GLYCATION END PRODUCT (AGE)(2003)2 
Formation of AGE 
1. Endogenously 
2. Exogenous sources- 
a, Tobacco smoke, for example, is a well-known exogenous source of AGEs. The      
    combustion of various pre-AGEs in tobacco during smoking gives rise to    
    reactive and toxic AGEs. Serum AGEs or LDL-linked AGEs are    
    significantly elevated in cigarette smokers. Diabetic smokers, as a result, are    
    reported to exhibit greater AGE deposition in their arteries and ocular lenses. 
b Diet is a significant exogenous source of highly reactive AGEs. Food   
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   processing, heating in particular, has a significant accelerating effect in the   
   generation of glyco- and lipoxidation products. 
   AGEs form at a constant but slow rate in the normal body, starting in early     
   embryonic development, and accumulate with time. However, their formation is     
   markedly accelerated in diabetes because of the increased availability of    
   glucose. 
                AGEs are a heterogeneous group of molecules formed from the    
         nonenzymatic reaction of reducing sugars with free amino groups of proteins,    
         lipids, and nucleic acids. The initial product of this reaction is called a Schiff     
         base, which spontaneously rearranges itself into an Amadori product, as is the     
         case of the well-known hemoglobin A1c (A1C). These initial reactions are  
         reversible depending on the concentration of the reactants. A lowered glucose    
         concentration will unhook the sugars from the amino groups to which they are  
         attached;conversely, high glucose concentrations will have the opposite effect, if  
         persistent.A series of subsequent reactions, including successions of    
        dehydrations, oxidation- reduction reactions, and other arrangements lead to the   
         formation of AGEs. Several  compounds, e.g., N-carboxymethyl-lysine,  
         pentosidine, or methylglyoxal derivatives, serve as examples of well-   
         characterized  and widely studied AGEs. 
         EFFECTS OF AGE 
1. Retinopathy 
2. Diabetic nephropathy- thickened glomerular basement membrane and 
mesangial expansion, are accompanied by accumulation of AGEs, leading to 
glomerulosclerosis and interstitial fibrosis 
3. Increased AGE accumulation in the diabetic vascular tissues has been 
associated with changes in endothelial cell, macrophage, and smooth muscle 
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cell function. In addition, AGEs can modify LDL cholesterol in such a way 
that it tends to become easily oxidized and deposited within vessel walls, 
causing streak formation and, in time, atheroma. AGE-crosslink formation 
results in arterial stiffening with loss of elasticity of large vessels 
         PROTEIN KINASE C(1998)12 
           The activation of protein kinase C (PKC) and increased diacylglycerol (DAG)    
           levels initiated by hyperglycemia are associated with many vascular  
           abnormalities in retinal, renal, and cardiovascular tissues. Among the various  
           PKC isoforms, the beta- and delta-isoforms appear to be activated    
           preferentially in the vasculatures of diabetic animals, although other PKC    
           isoforms are also increased in the renal glomeruli and retina. The glucose-    
           induced activation of  PKC has been shown to increase the production of   
           extracellular matrix and cytokines; to enhance contractility, permeability, and  
           vascular cell proliferation; to induce the activation of cytosolic phospholipase   
           A2; and to inhibit Na+-K+-ATPase. Treatment with D-alpha-tocopherol was    
           able to prevent many glucose-induced vascular dysfunctions and inhibit DAG-  
           PKC activation. 
          HEXASAMINE PATHWAY 13When glucose is high inside a cell, most of      
          that glucose is metabolized through glycolysis, going first to glucose-6   
         phosphate, then fructose-6 phosphate, and then on through the rest of the  
          glycolytic pathway. 
COMPLICATION OF DIABETES  
      (The DCCT Research group, 1993)14 
     Chronic complication includes 
     Microvascular 
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1. Retinopathy-Impaired vision,blindliess 
2. Nephropathy-Proteinuria,chronic kidney disease,dialysis 
3. Neuropathy- a, Peripheral: sensory and motor neuropathy 
                           b, Autonomic: gastroparaesis, postural hypotension, impotence 
Macrovascular 
1. Coronary artery disease-myocardial infraction 
2. Peripheral vascular disease-claudication,ulcers,amputation 
3. Cerebrovascular disease-stroke 
Oral disease(Petrou-Amerikanou et al,1998) 
1. Gingivitis                                   5.Oral lichen planus 
2. Periodontitis                              6. Oral cancer 
      3.   Xerostomia                                7. Leukoplakia 
4. Candidiasis 
     Acute complication 
1. hyperosmolar hyperglycemia 
2. Diabetic ketocidosis 
3. acute infections 
 ANALYSIS OF SALIVA IN DIABETES (SALIVARY PROTEMICS) 
• Salivary EGF levels reduced in diabetic patients  
• Salivary matrix metalloproteinase (MMP-8) levels and gelatinase (MMP-9)  
   Activities in patients with type 2 diabetes mellitus  
• Salivary thromboplastic activity in diabetics and healthy controls  
• Effects of diabetes mellitus on salivary secretion and its composition in the  
   human  
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• Levels of immunoglobulin A1 and messenger RNA for interferon gamma and tumor    
   necrosis factor alpha in total saliva from patients with diabetes mellitus type 2     
   with chronic periodontal disease  
• Structural and functional salivary disorders in type 2 diabetic patients  
Peck AB, Tanaka Y, Humphreys-Beher MG (2000) 15 
 
        Oral problems such as periodontitis are recognized major complications 
associated with diabetes. salivary derived growth factors, including epidermal growth 
factor (EGF), are thought to play a role in helping maintain levels of oral health, 
promoting wound healing, and maintaining mucosal integrity. In the present study, 
salivary levels of EGF in diabetic vs. healthy control patients was evaluated. Twenty-
one diabetic patients participated in this study. Age, race, sex and smoking histories 
were matched with 21 systematically healthy nondiabetic patients. Three milliliters of 
unstimulated resting whole saliva was collected from each patient at 6 h intervals up 
to 42 h and whole saliva protein concentrations were determined for each sample. 
EGF concentrations for each sample were quantitated spectrophometrically utilizing 
an immunoassay. Diabetic patients had greater salivary protein concentrations over 42 
h of collection with a mean of 1.502+/-0.09 vs. 1.242+/-0.05 mg/ml for healthy 
control patients. The EGF concentration was significantly lower (p<0.05) for the 
diabetic patients compared to control patients, whether expressed relative to 1 ml 
volume of saliva (873.43+/-106.5 vs. 1101.09+/-116.8 pg/ml) or 1 mg whole saliva 
protein (629.18+/-92.6 vs. 931.20+/-124.6 pg/mg saliva protein). This study suggests 
that reduced levels of salivary EGF in diabetic patients may contribute to the 
development of oral and systemic complications of diabetes, which may have future 
clinical applications. 
  29
Salo T, Ronka H, Konttinen YT [2000] 16they studied the salivary levels and 
activities of the matrix metalloproteinases (MMP) -8 and -9 in 45 type 2 diabetic 
patients and 77 control subjects. The patients' mean glycosylated haemoglobin 
(HbA1c) was 8.7%, indicating an unsatisfactory metabolic control of the disease. The 
MMP levels were further related to the clinical and microbiological periodontal 
findings as well as to salivary flow rate and other factors. The salivary flow rate, 
albumin and amylase concentrations were similar in type 2 diabetic patients to those 
in the control group. The mean gingival and periodontal pocket indexes were higher 
in the diabetes group. The number of potential periodontontal pathogenic bacteria was 
lower, however, in the diabetic than in the control group. Zymography and 
immunoblotting revealed that the major MMPs in the type 2 diabetic patients' saliva 
were MMP-8 and MMP-9. Salivary MMP levels and activities in type 2 diabetic 
patients were in general similar to those in the control group. However, the correlation 
coefficients using multiple regression analysis revealed that gingival bleeding, pocket 
depths and HbA1c were associated with increased MMP-8 levels which, in turn, were 
negatively predicted by elevated plasma lipid peroxide levels in the diabetic group, 
data on salivary MMP-8 and -9 do not support the concept of generalized neutrophil 
dysfunction in unbalanced diabetes. Moreover, plasma lipid peroxidation levels 
reflecting the increased oxidative burden, which is generated mainly by triggered 
neutrophils, do not indicate neutrophil dysfunction due to diabetes, but may rather be 
related to the increased tissue damage in an uncontrolled disease. However. advanced 
periodontitis in type 2 diabetes seems to be related to elevated salivary MMP-8 levels 
which might be useful in monitoring periodontal disease in diabetes. 
       Akyuz S, Ipbuker A, Emekli N [Mar 2004] 17Coagulative function of saliva 
derives from the thromboplastin found in saliva. It may establish hemostasis in the 
mouth. salivary disfunction and changes in salivary composition and are frequent 
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complications of diabetes. This study investigated the influence of some local 
etiologic and systemic factors on salivary thromboplastic activity (STA) in diabetics. 
In this study, cytological smears and biochemical tests were used. STA was measured 
by Quick's one stage method, serum glucose by the glucose oxidase method, and 
salivary protein by the method of Lowry. STA was almost the same in the diabetic 
and control groups. The only statistically significant difference within the diabetic 
group was found to be due to antibiotic usage. STA, i.e. clotting time, was 30% longer 
(114 s) ( p<0.05) and salivary protein (4.07 mg ml(-1)) ( p<0.1) was lower in diabetics 
not taking antibiotics than in those taking them. No such differences were observed in 
the healthy controls. Significant linear correlations ( p<0.05) with respect to STA 
were with salivary protein in the control group (r=0.61) and in the diabetic group 
(r=0.51) and with antibiotic usage (r=0.29), with leukocyte cell count (r=0.27) in the 
diabetic. 
      Francisco H, Santos C, Mesquita MF (2004)18This study investigated the effects 
of diabetes mellitus (types I and II) on human salivary gland function compared to 
healthy age-matched controls. The results have shown that both type I and type II 
diabetic patients secrete significantly (p < 0.05) less resting and stimulated saliva 
compared to healthy age-matched controls (AMC). It was also found that the diabetic 
patients have an increased resting and stimulated salivary protein concentration 
compared to healthy participants. However, the secretory capacity (stimulated minus 
resting values) was markedly reduced compared to controls. The level of calcium 
(Ca2+) in the saliva of diabetic patients was significantly (p < 0.05) elevated 
compared to the AMC. In contrast, the levels of magnesium (Mg2+), zinc (Zn2+) and 
potassium (K+) in the saliva of diabetic patients were significantly (p < 0.05) reduced 
compared to the values obtained in AMC. These results indicate that diabetes mellitus 
can lead to marked dysfunction of the secretory capacity of the salivary glands. In 
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these patients a modified fluid, organic and inorganic salivary secretion may be 
responsible for the increased susceptibility to oral infections and impaired wound. 
      Afonso-Cardoso SR, Buso AM [Jun 2006] 19Diabetes mellitus and periodontal 
disease have high incidence in the general population and are associated with various 
degrees of dysfunction in the immune system. It has been shown that diabetic patients 
with severe periodontal disease have more complications of diabetes and less 
effective metabolic control compared with diabetic patients with healthy gingiva. 
Patients with diabetes and severe periodontal disease present higher levels of serous 
immunoglobulin A (IgA). Elevation of the IgA1 isotype is thought to contribute to 
this phenomenon. Another important event in the diabetes-periodontitis association is 
the disturbance in local and systemic production of inflammatory cytokines. In this 
study they tested the hypothesis that type 2 diabetic patients with chronic moderate 
periodontal disease have differences in salivary IgA1 titers and cytokine expression 
when compared with the chronic severe periodontal disease cases. We utilized a 
jacalin-IgA capture assay to determine the IgA1 titers in total saliva and reverse 
transcriptase-polymerase chain reaction to detect mRNA for interferon gamma (IFN-
gamma) and tumor necrosis factor alpha (TNF-alpha) in total saliva samples of 13 
patients with chronic moderate periodontal disease and 10 with chronic severe 
periodontal disease, they observed a predominance of IgA1 titers of 64 (45.5%) in 
saliva samples from chronic severe periodontal disease patients and titers averaging 
512 (30.8%) in chronic moderate periodontal disease patients.  Detected mRNA for 
IFN-gamma in six out of 10 chronic severe periodontal disease subjects and in two 
out of 13 chronic moderate periodontal disease patients. TNF-alpha expression was 
similar in both groups, data suggest that higher levels of IgA1 may exert partial 
protection of the periodontal tissue in chronic moderate periodontal disease diabetic 
patients when compared to severe periodontal disease. Despite the small number of 
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patients, IFN-gamma expression had a trend association with severity of periodontitis 
and TNF-alpha gene expression did not correlate with peridontitis. 
      Salom L, Gomez de Ferraris ME [Jul 2006] 20Diabetes mellitus type 2 is the 
most common metabolic disorder and it causes an important morbimortality. The 
structural modifications in the parotid gland (sialosis) had already been described in 
these patients and could result in variations in the salivary composition, as well as an 
increase in periodontal and dental pathology.: To compare the biochemical findings in 
the saliva and to correlate these biochemical disturbances with the morphologic 
findings previously described. Clinical information were gathered about 33 patients, 
17 had type 2 diabetes. Samples of whole saliva were obtained for biochemical 
analysis and serum samples to determine metabolic control. In the diabetics saliva 
they found urea and total proteins increased and reduced levels of microalbumina. 
salivary glucose was only augmented in patients with poor metabolic control. Clinical 
symptoms of xerostomia were present in 76,4% and dental and periodontal disease in 
100%. The parotid gland was characterised by the presence of small acini, lipid 
intracytoplasmic droplets, as well as adipose stroma infiltration. The acinar 
cytoqueratins expression was heterogeneous and very positive in the hyperplasic 
ducts. These biochemical disorders in the saliva of the type 2 diabetic patients would 
be related with the structural changes previously observed in parotid gland 
 
VARIOUS METHODS OF SALIVARY GLUCOSE ESTIAMTION 
Gough H, Luke G. A, Beeley J. A. (1996) 21Determination of glucose concentrations 
in small volumes of unstimulated fasting whole saliva. The technique involves high-
performance ion-exchange chromatography at high pH and pulsed amperometric 
detection. It has a high level of reproducibility, a sensitivity as low as 0.1 μmol/l and 
requires only 50 μl samples. The procedure can be used for the analysis of other 
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salivary carbohydrates and for monitoring the clearance of dietary carbohydrates from 
the mouth. 
     Di Gioia ML, Leggio A (2004) 22 The methodology was developed for the 
determination of human salivary glucose concentration. The technique involves the 
glucose derivatization with acetic anhydride and subsequent analysis of glucose 
penta-acetylated by gas chromatography combined with mass spectrometry. Glucose 
concentration in the biological fluid depends on the physiological status of the donor. 
     Schlapfer P, Mindt W and Racine P.H. (1974) 23Glucose concentrations of 
biological samples can be conveniently measured using glucose oxidase and the 
standard oxygen electrode. Blood samples are an exception because the variable 
oxygen concentration of the contained hemoglobin affects the results to avoid this 
error , Hexacyanoferrate(III), a threshold-type acceptor, proved to be satisfactory for 
glucose measurements. 
   George G. Guilbault, Palleschi G(1995)24  Biosensors have been developed and 
applied for the non invasive determination of metabolites in body fluids. Advantages 
of saliva or sweat analysis are the ease of sample collection and that samples can be 
collected more frequently with much less stress on the patient. The biosensor was 
applied to the determination of sera and saliva glucose content. 
CORRELATION BETWEEN SALIVA GLYCATED AND BLOOD 
GLYCATED PROTEINS  
   Ichiro N, Kanehisa M, TatsuyaT (2003) 25Blood and saliva samples of 51 male 
workers were collected. The fructosamine and hydrazine methods were used to 
measure saliva glycated protein. HbA1c, fructosamine and blood glucose were 
measured as indices of blood glycated protein, and the correlation between blood 
glycated protein and saliva glycated protein was examined . Saliva fructosamine 
glycated protein showed a significant correlation with HbA1c and blood glucose. 
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Blood glycated protein and blood glucose could be estimated by measuring saliva 
glycated protein. 
     Forbat LN, Collins RE, Maskell GK, Sönksen PH. (1981)26 Glucose 
concentration in venous blood and parotid saliva taken from 31 diabetics attending a 
diabetic clinic showed values ranging respectively from 3.9 to 19.1 mmol/l and 0.06 
to 0.83 mmol/l (means 9.6 mmol/l and 0.32 mmol/l respectively). Linear regression of 
salivary glucose on blood glucose gave a simple correlation coefficient of 0.18 (NS). 
Since salivary glucose levels did not reflect blood glucose levels, the possibility of 
diabetics regulating their metabolic control by the noninvasive technique of 
monitoring salivary glucose concentrations is not possible 
SCREENING OF DIABETES MELLITUS WITH GINGIVAL CREVICULAR 
BLOOD  
   Müller HP, Behbehani E (2004)27 To test the feasibility of using gingival crevice 
blood (GCB) collected during routine periodontal examination to estimate blood 
glucose levels using a novel and very sensitive self-monitoring device Forty-six 
patients (20 male, 26 female; age range 12-56 years, mean age 36 +/- 11 years) 
seeking dental treatment took part in the study. 24 had gingivitis, of which 22 were 
moderate or advanced periodontitis. Periodontal probing depth (PD) and clinical 
attachment loss was measured at 6 sites of every tooth present, and bleeding on 
probing (BOP) was recorded. A site with profuse BOP was chosen for glucose 
determination. Measurements in GCB were compared with those of conventional 
capillary fingerstick blood (CFB) Agreement between the two measurements was 
low, the mean difference was -1.22.The present study failed to provide any evidence 
for the usefulness of GCB for testing blood glucose during routine periodontal 
examination. 
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   Beikler T, Kuczek A, Petersilka G, Flemmig TF(2002) 28 Diabetes mellitus (DM) 
is undiagnosed in approximately 1/2 of the patients actually suffering from the 
disease. In addition, the prevalence of DM is more than 2x as high in patients with 
periodontitis when compared to periodontally healthy subjects, thus a high number of 
patients with periodontitis may have undiagnosed DM, blood oozing from gingival 
tissues during routine periodontal examination can be used for determining glucose 
levels. 32 non-diabetic and 13 diabetic patients with moderate to severe periodontitis 
were enrolled and subjected to routine clinical periodontal examination. Periodontal 
pocket probing was performed using a standard force. Blood oozing from gingival 
tissues of anterior teeth following periodontal pocket probing was collected with the 
stick of a glucose self-monitoring device (Elite(R) 2000, Bayer Diagnostics GmbH, 
Munich). As control, fingerstick capillary blood was taken. Statistical analysis was 
performed by Pearson's correlation coefficient. The results suggested that blood 
oozing during routine periodontal examination may be used for diabetes mellitus 
screening in a dental office setting. 
   Khader YS, Al-Zu'bi BN, Judeh A, Rayyan M (2006) 29.This study was 
conducted to assess the usefulness of the gingival crevicular blood for estimating the 
glucose level during routine periodontal examination using Xitux Diagnostics Smart-
X self-monitoring blood glucose device among Jordanian patients attending dental 
teaching clinics. A total of 34 type 2 diabetic patients (18 males and 16 females) and 
26 non-diabetic patients (14 males and 12 females) participated in this study. Glucose 
level was measured in a sample of gingival crevicular blood and in another sample 
obtained by finger puncture using a self-monitoring device. Glucose measurements 
from gingival crevicular blood samples, ranged from 57 to 250 mg dl-1 with a mean 
of 125.4+/-60.7 mg dl-1 (+/-SD) and glucose measurements obtained by finger 
puncture, ranged from 62 to 263 mg dl-1 with a mean of 131.9+/-61.1 mg dl-1. 
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Pearson's correlation coefficient was performed to assess the correlation between the 
glucose measurements in these two samples. gingival crevicular blood can provide an 
acceptable source for measuring blood glucose level. However, the technique to 
obtain an acceptable blood sample from gingival crevices is not always feasible which 
would limit its application as a clinical practice. Additional studies that refine this 
technique and use larger sample size are recommended. 
   Yamaguchi M, Kawabata Y, Kambe S, Wårdell K, Nystrom FH, Naitoh K, 
Yoshida H (2004 May)30 To realize a non-invasive blood glucose monitor, the 
gingival crevicular fluid (GCF) was measured. A GCF-collecting device was 
developed that was designed to be disposable, biocompatible and small enough to be 
inserted in the gingival crevice for collection of a sub-microlitre sample of GCF. 
Also, a high-sensitivity glucose testing tape incorporated in the device was developed. 
Red laser light in a portable optical device measured the colour density of the testing 
tape. It was suggested that GCF could be used as a method of non-invasive blood 
glucose measurement as where was positive correlation with the blood glucose level 
ORAL MANIFESTATION OF DIABETES  
DIABETES AND PERIODONTITIS 
       Beena VT, Nair RG, Vijayakumar [1995] 3Immunoglobulin in the saliva of 
diabetic patients with periodontitis The study was conducted to estimate the 
concentration of immunoglobulins in the saliva of diabetic and nondiabetic patients 
with periodontitis. The salivary immunoglobulins G, A and M (IgG, IgA, IgM) were 
determined in 50 patients with type II or noninsulin dependent diabetes mellitus 
(NIDDM) and 50 non diabetic patients with periodontitis. The values were compared 
with that of 50 age and sex matched controls. IgG, IgA were found to be significantly 
increased in diabetic patients with periodontitis, compared to nondiabetic patients and 
controls. Though an increase in IgM was found in diabetic patients it was not 
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significant. The altered immune response observed may be due to the response to a 
greater antigenic challenge which in turn may be responsible for the increased 
incidence of periodontitis. 
       Cucinotta M, Cicciu D, Passi P, Teti D [Sep 2006] 31Salivary histamine level as 
a predictor of periodontal disease in type 2 diabetic and    non-diabetic subjects Some 
previous investigations underscored the role of histamine in periodontal disease, 
especially in diabetic patients, but the behavior of this inflammatory mediator in the 
early phases of periodontal involvement remains unclear. The aim of the present study 
was to correlate the presence of histamine in saliva with clinical parameters in 
healthy, periodontitis-affected, and diabetic subjects to ascertain whether this amine 
may serve as a predictive index of periodontal risk.: For this purpose, subjects were 
selected as follows: 1) with newly diagnosed type 2 diabetes mellitus; 2) with neither 
diabetes nor periodontitis; 3) with no diabetes but with chronic, untreated periodontal 
disease. Histamine salivary levels were measured at the initial time (T0) and after 6, 
12, and 24 months using high-performance liquid chromatography. The main 
periodontal indexes were recorded at the same time intervals. At T0, a very typical 
shape of the histamine chromatogram was found for all patients of the three groups; at 
this time, the salivary histamine levels of diabetic patients were increased and 
comparable to those of healthy patients with periodontal disease, whereas healthy 
subjects with no periodontitis showed reduced histamine levels. Further controls at 6, 
12, and 24 months showed a statistically significant correlation between the increase 
of salivary histamine and the worsening of the periodontal indexes in diabetic and 
non-diabetic subjects 
   Yamalik N, Ozer N, Ersoy F, Yeniay I [1996] 32 
 
The alterations of whole saliva constituents in patients with diabetes mellitus   
The present study was undertaken in order to determine the possible alterations in 
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whole saliva and the periodontal status in patients with diabetes mellitus (DM), and 
was conducted on 17 patients with DM and 17 systemically and periodontally healthy 
subjects. When the subjects were evaluated clinically, significantly increased probing 
depths were noticed in the DM group when compared with the healthy subjects. In 
whole saliva samples, sodium, potassium, total protein, amylase, thiocyanate, and 
secretory IgA levels were determined in both groups. Difference between the two 
groups regarding the mean salivary potassium levels were found to be statistically 
significant since the mean salivary potassium levels in the DM and the control groups 
were 2.470 +/- 9.04 mmol/L and 14.30 +/- 8.88 mmol/L, respectively. The mean 
salivary total protein, amylase and secretory IgA levels in the DM group were 2.41 +/- 
1.0 mg/mL, 124.2 +/- 79.7 U/mL and 6.86 +/- 3.50 mg/L, all being significantly 
higher than the control group. However, no significant differences could be shown for 
the salivary sodium and thiocyanate levels. Nor was there any difference between 
non-insulin dependent diabetes mellitus (NIDDM) and insulin-dependent diabetes 
mellitus (IDDM). The findings of the present study suggest that, besides the clinical 
examinations, the determination of the possible alterations in the composition of 
whole saliva might also be helpful in understanding the increased severity of 
periodontitis.  
   Diabetes mellitus and oral lichen planus   
Van Dis M, Parks E. (2009)33-The purpose of this study was to determine the 
prevalence of oral lichen planus in a population of patients with diabetes mellitus 
compared with a control population and to determine if patient medications had any 
influence on the presence of such lesions. Two hundred seventy-three patients with 
diabetes and an identical number of age-, gender- and race-matched controls were 
examined for clinical evidence of oral lichen planus. Patient medication histories were 
  39
also obtained from each group. Eleven diabetic patients (4%) and eight control 
patients (3%) had clinical evidence of oral lichen planus. Ingestion of nonsteroidal 
anti-inflammatory drugs or angiotensin-converting enzyme inhibitors was associated 
with the presence of oral lichen planus lesions in six patients. There was no apparent 
association of diabetes and oral lichen planus in this population, and the ingestion of 
medications known to cause lichenoid mucosal reactions had no influence per se on 
the presence of oral lichen planus lesions (p>0.05). However, the type of medication 
ingested by those patients who had oral lichen planus lesions was either nonsteroidal 
anti-inflammatory drug or angiotensin-converting enzyme inhibitor, which was a 
significant association (p<0.00). 
    Petrou-Amerikanou C; Markopoulos A K; Belazi M; Karamitsos D; 
Papanayotou P (1998)34The purpose of the present study was to determine the 
prevalence of oral lichen planus (OLP) in a population of patients with diabetes 
mellitus (DM) as compared with a control population. One hundred and thirty-nine 
patients with type I DM, 353 patients with type II DM and 274 controls were 
examined for clinical evidence of OLP. The clinical evidence of OLP in the diabetic 
and control patients was confirmed by histopathological examination The prevalence 
of OLP in type I diabetic patients was 5.76%, in type II 2.83%, and 1.82% in the 
controls. The prevalence of OLP was significantly higher in patients with type I DM 
and slightly higher in patients with type II DM in comparison to the prevalence in the 
control sample. The fact that type I diabetes and OLP are characterized by 
autoimmune phenomena and T cell immune responses respectively, suggest that the 
immune system may play a critical role in the appearance of OLP in patients with 
type I DM. 
  Bagan JV, Donat JS, Penarrocha M, Milian MA, Sanchis JM (1993) 35 -A study 
was made of 72 patients with oral lichen planus associated (n = 28) or not with 
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diabetes mellitus (n = 44). No significant differences were observed between both 
groups in terms of the location of the lichen planus lesions on the buccal mucosa, 
palate, gums or floor of the mouth. On the other hand, the diabetics exhibited a greater 
frequency of oral lichen planus on the tongue. Atrophic-erosive lesions were more 
common in patients with lichen planus associated with diabetes 
Oral leukoplakia and diabetes mellitus 
Albrecht M, Bánóczy J, Dinya E, Tamás G Jr. (1992) 36-The occurrence of oral 
leukoplakia in 1600 patients with diabetes mellitus (815 type 1: insulin-dependent, 
761 type 2: non-insulin-dependent)-under care at the International Medicine 
Department-was studied. Precancerous lesions and conditions were diagnosed and 
grouped according to internationally accepted criteria. The prevalence of oral 
leukoplakia in diabetic patients was 6.2%, as compared to 2.2% in the healthy 
controls. Leukoplakia  showed the highest occurrence in the second year of 
established diabetes, and their prevalence was higher among insulin-treated diabetics. 
Smokers were more often affected 
Diabetes mellitus and tumors of the oral cavity 
Ujpál M, Matos O, Bíbok G, Somogyi A, Szigeti K, ( 2004 Apr) 37Diabetes mellitus 
(DM) is a risk factor for the development of periodontal diseases and various 
inflammatory lesions in the oral mucosa. A possible correlation between DM and oral 
premalignancies and tumors was examined in this study. Stomato-oncological 
screening was carried out on 200 DM patients in the medical departments: The lesions 
found were classified in three groups: inflammatory lesions, benign tumors and 
precancerous lesions. Benign tumors were found in 14.5%, and precancerous lesions 
in 8% of diabetics.A retrospective DM screening of 610 inpatients with histologically 
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confirmed oral malignancies was also performed. The control group comprised 574 
complaint- and tumor-free adults. Fasting blood glucose levels were determined in 
both groups, and the tumor location was registered in the cancer patients. The 
combination of DM and smoking means a higher risk for oral precancerous lesions 
and malignancies. DM may be a risk factor for oral premalignancies and tumors. 
Diabetes mellitus in odontogenic infections and oral candidiasis 
Ueta E, Osaki T, Yoneda K, Yamamoto T. (1993 Apr) 38 -The prevalence of 
diabetes mellitus (DM) in odontogenic infections and oral candidiasis was examined, 
and influences of DM on the clinical manifestations of the infections and neutrophil 
functions were investigated. Among 21 severe and 221 mild odontogenic infections, 
DM was detected in 5 cases in each group. Of 64 cases of symptomatic oral 
candidiasis, 8 cases were complicated with DM which was detected by blood 
examination during treatment. During the period of infection, the mean fasting blood 
sugar level was 16.0 +/- 4.4 and 9.8 +/- 1.2 mmol/l in the DM-complicated 
odontogenic infections and candidiasis, respectively. All white blood counts,  
C-reactive protein levels and erythrocyte sedimentation rates were more elevated in 
DM(+) odontogenic infection cases than in DM(-) ones. In DM(+) candidiasis. The 
polymorphonuclear leukocytes from diabetic patients, especially those with 
candidiasis, produced less free oxygen radicals and exhibited reduced phagocytosis 
and intracellular killing of Candida cells associated with this reduced O2- generation 
during the infection. These suppressed neutrophil functions increased after treatment 
but did not reach control levels. These results indicate that DM is a predisposing 
condition for odontogenic infections and oral candidiasis. DM-complicated infections 
become severe because of neutrophil suppression, and that examination of blood 
sugar level should be essential for patients with oral infections 
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   Geerlings SE, Hoepelman AI (1999 Dec) 39-Patients with diabetes mellitus (DM) 
have infections more often than those without DM. The course of the infections is 
also more complicated in this patient group. One of the possible causes of this 
increased prevalence of infections is defects in immunity, no disturbances in adaptive 
immunity in diabetic patients have been described. Different disturbances (low 
complement factor 4, decreased cytokine response after stimulation) in humoral 
innate immunity have been described in diabetic patientscellular innate immunity 
most studies show decreased functions (chemotaxis, phagocytosis, killing) of diabetic 
polymorphonuclear cells and diabetic monocytes/macrophages compared to cells of 
controls. In general, a better regulation of the DM leads to an improvement of these 
cellular functions. Furthermore, some microorganisms become more virulent in a high 
glucose environment. Another mechanism which can lead to the increased prevalence 
of infections in diabetic patients is an increased adherence of microorganisms to 
diabetic compared to nondiabetic cells. This has been described for Candida albicans. 
Possibly the carbohydrate composition of the receptor plays a role in this 
phenomenon. 
   Soysa NS, Samaranayake LP, Ellepola AN (2006 May) 40 -It has been reported 
that poor glycaemic control predisposes to oral candidal infection in diabetic patients. 
For instance, the carriage of Candida species and the density of candidal growth in the 
oral cavity is frequently claimed to be increased in patients with diabetes mellitus. 
   Darwazeh AM, MacFarlane TW, McCuish A, Lamey PJ (1991 Jul) 41-The 
glucose concentration in unstimulated mixed saliva and serum was assayed and 
correlated with oral candidal colonization in 41 diabetics and 34 healthy control 
subjects. In diabetic patients, salivary glucose concentration was significantly higher 
than in the controls and was directly related to blood glucose concentration ,diabetic 
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patients who carried Candida intraorally had significantly higher salivary glucose 
concentrations than those in whom Candida could not be isolated 
Xerostomia in diabetes mellitus 
Sreebny LM, Yu A, Green A, Valdini A (1992 Jul) 42-The prevalence of xerostomia 
in a group of ambulatory diabetic patients and to compare the following in patients 
with and without xerostomia: 1) flow rates of saliva and lacrimal fluid, 2) the 
presence of other symptoms suggestive of oral and extraoral dryness, 3) indexes of 
glycemic control, and 4) noninvasive measures of cardiovagal autonomic nervous 
system function .Forty adult diabetic patients and an equal number of age- and sex-
matched healthy nondiabetic control subjects were studied .A questionnaire was 
administered to all patients, and the following tests were performed: resting and 
stimulated flow rates on whole saliva; Schirmer's test (lacrimal fluid), serum glucose 
and HbA1, expiration-inspiration ratio, 30:15 ratio, Valsalva ratio, and the systolic 
blood pressure response to standing .The salivary flow rates of the diabetic subjects 
was consistently lower than those of healthy, nondiabetic control subjects. The mean, 
resting, and whole-saliva flow rate was abnormally low in the diabetic patients who 
complained of xerostomia; Dry mouth is a common complaint among ambulatory 
diabetic patients. It is strongly associated with objective measurements of poor 
salivary flow and with other oral and extraoral symptoms 
   Moore PA, Guggenheimer J, Etzel KR, Weyant RJ, Orchard T (2001 Sep) 43 -
The Oral Health Science Institute at the University of Pittsburgh has completed a 
cross-sectional epidemiologic study of 406 subjects with type 1 diabetes and 268 
control subjects without diabetes that assessed the associations between oral health 
and diabetes. This report describes the prevalence of dry-mouth symptoms 
(xerostomia), the prevalence of hyposalivation in this population, and the possible 
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interrelationships between salivary dysfunction and diabetic complications .The 
subjects with diabetes were participants in the Pittsburgh Epidemiology of Diabetes 
Complications study who were enrolled in an oral health substudy. Control subjects 
were spouses or best friends .Of the medical diabetic complications studied (ie, 
retinopathy, peripheral and autonomic neuropathy, nephropathy, and peripheral 
vascular disease), only neuropathy was found to be associated with xerostomia and 
decreased salivary flow measures .Subjects with type 1 diabetes who had developed 
neuropathy more often reported symptoms of dry mouth as well as symptoms of 
decreased salivary flow rates. 
ESTIMATION OF SALIVARY AGE LEVEL 
Grootveld M, Christopher J.L, Silwood 44 -The applications of high resolution 1H 
NMR analysis as a diagnostic probe for human saliva are reviewed with special 
reference to diabetes mellitus, and a recently published report regarding the ability of 
this technique to detect advanced glycation endproducts (AGEs) in this biofluid 
   Zidek W, Henning L, Schluter H [Oct 2004] 6 Patients with diabetes mellitus are 
prone to develop increased advanced glycation endproducts causing local 
complications and increased overall morbidity and mortality. Nuclear magnetic 
resonance spectra were determined in saliva of 52 consecutive patients with diabetes 
mellitus and 47 age-matched healthy control subjects. Resonance spectra showed 
specific peaks at 2.3, 7.3, and 8.4 ppm in saliva from patients with diabetes mellitus. 
These peaks could be generated by incubation of saliva from healthy control subjects 
with hypochloric acid in vitro, indicating the presence of advanced glycation 
endproducts. The presence of advanced glycation endproducts in patients with 
diabetes mellitus was associated with approximal plaque index, indicating increased 
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periodontal damage. The study indicates that increased advanced glycation 
endproducts are involved in the pathogenesis of diabeticcomplication 
USE OF NMR IN PREDICTION OF DIABETES RISK 
  Chatellier G, Menard J, Panhard X, (2007) 45 -It has been proposed that nuclear 
magnetic resonance (NMR) plasma analysis can improve lipoprotein subclass 
discrimination and predict coronary artery disease (CAD) the mortality and morbidity 
for CAD in type 2 diabetes patients is two to four times higher than in nondiabetic 
subjects, making cardiovascular disease the first cause of death and disability amongst 
this population. Moreover, CAD is often undetected in diabetic patients. To assess 
whether NMR spectroscopy can predict cardiovascular disease a randomized clinical 
trial, involved high-risk type 2 diabetic patients who were followed for 4 years and 
who, during that period, had fatal or nonfatal acute myocardial infarction Patients of 
the ‘case’ group were defined as those who presented either a fatal or nonfatal acute 
myocardial infarction or who underwent sudden death during the 4-year follow-up. 
Control patients were defined as patients not presenting any cardiovascular events. 
Control patients were matched to the case patients for age ± 2 years, sex and 
geographical origin obtained blood samples after an overnight fast, using tubes 
without anticoagulant, stored sera at −80 °C before NMR analysis., acquired spectra 
at 500 MHz (Varian Inova) with a 1.5-s presaturation of the water signal the 
discriminatory capacity of multivariate analyses of NMR spectroscopic data is not 
high enough to render the technique feasible for clinical use. With respect to 
cardiovascular risk prediction, global statistical analyses, including classical 
biochemical and clinical risk factors at baseline, should be considered in addition to 
NMR data. 
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   Hodge AM, Jenkins AJ, English DR, O'Dea K, 2009 Jan 46 To determine 
whether nuclear magnetic resonance (NMR)-determined lipoprotein profiles predict 
type 2 diabetes. 813 male and female participants in the Melbourne Collaborative 
Cohort Study, aged 40-69 years at baseline (1990-1994), and with a baseline fasting 
plasma glucose <7.0mmol/L. Incident type 2 diabetes was identified in 1994-1998. 
Concentration of very low density lipoprotein (VLDL) particles (positive) and high 
density lipoprotein (HDL) particle size (negative) were selected by stepwise 
regression as predictors of type 2 diabetes. Factor analysis identified a factor from 
NMR variables, explaining 47% of their variation, and characterized by a positive 
correlation with VLDL, particularly large and medium sized; more low density 
lipoprotein (LDL) that were smaller; and relatively smaller, but not more HDL 
particles. This factor was positively associated with diabetes incidence, but not 
independently of triglycerides. identified an atherogenic NMR lipoprotein profile in 
people who developed diabetes, but this did not improve diabetes prediction beyond 
conventional triglyceride levels. 
Cotch MF, Jenkins AJ, Shea S (2009) 47 
To examine the associations between nuclear magnetic resonance (NMR) defined 
lipoproteins and diabetic retinopathy (DR) in a population-based sample of adults 
with type 2 diabetes. 921 persons with diabetes in the Multi-Ethnic Study of 
Atherosclerosis (MESA) were included. DR was assessed from retinal photographs. 
Lipoproteins were measured by NMR spectroscopy. The lack of association between 
NMR-defined lipoproteins and DR does not support clinical use of NMR 
spectroscopy for management of patients with DR. 
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VARIOUS USES OF NMR TECHNIQUE  
Silwood  C.J.L, Lynch A.W.D, Claxson (2002)48- NMR technique was used to 
detect 60 metabolites from oral health care products 
 Takeda I , Stretch C,  Bhatnager K(2009)49 
NMR was used to measure metabolites from saliva of smokers and nonsmokers and 
found that citrate, lactate, pyruvate, and sucrose to be higher and formate to be lower 
in concentration in smokers compared with non-smokers 
   Harada H,  Shimizu H,  Maeiwa M(1987)50 NMR was applied to the study of 
metabolites in human saliva specimens. Acetate, lactate, ethanol, glucose and some 
other substances were simultaneously identified and quantitated from the (1)H-NMR 
spectra of saliva specimens treated with D2O. The experiments demonstrated the 
value of (1)H-NMR as an analytical method in the field of forensic science and clinical 
pathology and toxicology. 
   Michael Y. Tsai, Poulos AG (2004)51 NMR is used as an alternative method for the 
measurement of postprandial TG-rich lipoproteins ,Chylomicron and chylomicron 
remnant/VLDL fraction in individuals consuming a high-fat meal.  
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Age and gender of subjects in the study groups (Table 1, Graph I) 
The study population comprised of 75 patients, 25 in group I, 25 in group II, and 25 in 
group III. There were 35 males (Group I = 8, Group II = 14, group III = 13) and 40 
females (Group I = 17, Group II = 11, group III = 12). The mean age in group I was 
(males = 57.57 ± 12.69, females = 50.72 ± 7.47). The mean age in group II was 
(males = 58.57 ± 6.80 , females = 51.27 ± 10.00). The mean age in group III was 
(males = 54.42 ± 8.15, females = 51.67 ± 8.06). 
Mean random blood glucose in each group (Table II, Graph II) 
The mean blood glucose values in mg/dl were,  
Group I  87.08 (± 18.07), Group II  257.44 (± 54.47) and Group III  79.86 (± 17.05)  
There was statistically significant difference between group I and II and between group II 
and group III (p = 0.000**)  
There was no statistically significant difference between group I and III (p = 0.742)   
Mean HbA1C in the study population (Table III, Graph III) 
The mean HbA1C values in % were,  
Group I   6.7 (± 1.4), Group II   8.6 (± 1.8) and Group III   4.9 (± 0.80)  
 There was statistically significant difference between group I and II, group I and III and 
group II and III (p = 0.000**) 
Mean salivary glucose in the study population (Table IV, Graph IV) 
The mean salivary glucose values in mg/dl were, 
Group I   9.7(±7.6), Group II   12.1(± 9.6) and group III    8.6(± 7.5)  
 The difference was not statistically significant between any of the two groups 
Group I and II (p = 0.357), Group I and III (p = 0.927), Group II and III (p = 0.356) 
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Mean salivary AGE in the study population (Table V, Graph V) 
The mean salivary AGE values in ppm were, 
Group I   3.5 (± 1.2), Group II   6.3 (± 2.11), group III    1.99 (± 0.80) 
There was statistically significant difference between group I and II and between Group 
II and III (p = 0.000**). There was no statistically significant difference between group I 
and III (p = 0.180) 
Pearson’s correlation analysis of random blood glucose with HbA1C in the study groups: 
(Table VI, Graph VIa, VIb ,VIc and VId ) 
Pearson’s correlation analysis of random blood glucose with HbA1C showed statistically 
significant negative correlation in group I (r = -0.546, p = 0.005**). There was positive 
correlation which was not statistically significant in group II (r = 0.242, p = 0.243) and 
group III (r =0.113, p = 0.591) 
There was highly significant positive correlation when all the groups (I, II, III) were 
assessed together (r = 0.620, p = 0.000**) 
Pearson’s correlation analysis of random blood glucose with salivary glucose between all 
the groups: (Table VII, Graph VIIa, VIIb, VIIc and VIId) 
Pearson’s correlation analysis of random blood glucose with salivary glucose showed 
Non significant negative correlation in group I (r = -0.119, p = 0.572), positive 
correlation which was statistically insignificant in group II (r = 0.351, p = 0.086) and 
Significant negative correlation in group III (r = -0.414, p = 0.040*)  
There was statistically non significant positive correlation when all groups (I, II, III) were 
assessed together (r = 0.199, p = 0.086). 
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Pearson’s correlation analysis of salivary glucose and salivary AGE between all groups: 
(Table VIII, Graph VIIIa, VIIIb, VIIIc and VIIId) 
Pearson’s correlation analysis of salivary glucose and salivary AGE showed statistically 
non significant negative correlation in group I (r = -0.083, p = 0.799), statistically non 
significant positive correlation in group II (r = 0.134, p = 0.573) and group III                         
(r = 0.291, p = 0.576). 
Statistically significant negative correlation was observed when all groups (I, II, III) were 
assessed together (r = -0.380, p = 0.019*). 
Pearson’s correlation analysis of salivary AGE and HbA1C between all the groups 
(Table IX, Graph IXa, IXb, IXc and IXd) 
Pearson’s correlation analysis of salivary AGE and HbA1C showed statistically non 
significant negative correlation in group I (r = -0.100, p = 0.758), statistically non 
significant positive correlation in group II (r = 0.095, p = 0.692) and group III (r = 0.433,  
p = 0.391) 
Statistically significant negative correlation was observed when all groups (I, II, III) were 
assessed together (r = -0.419, p = 0 .009**) 
Pearson’s correlation analysis of blood glucose and salivary AGE between all the groups 
(Table X, Graph Xa, Xb, Xc and Xd) 
Pearson’s correlation analysis of blood glucose and salivary AGE showed statistically 
non significant positive correlation in group I (r = 0.199, p = 0.556) and group II  
(r = 0.126, p = 0.598). There was statistically significant negative correlation in group III 
(r = -0.852, p = 0.031*)  
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Statistically significant negative correlation was observed when all groups (I, II, III) were 
assessed together (r = -0.369, p = 0.022*) 
Pearson’s correlation analysis of salivary glucose and periodontal status between all the 
groups (Table XI, Graph XI) 
Pearson’s correlation analysis of salivary glucose and periodontal status showed 
statistically significant positive correlation between salivary glucose and periodontal 
status when all groups were assessed together (r = 0.245, p = 0.034*).        
Pearson’s correlation analysis of salivary AGE and periodontal status between all the 
groups (Table XII, Graph XII) 
Pearson’s correlation analysis of salivary AGE and periodontal status showed statistically 
significant positive correlation between salivary AGE and periodontal status when all 
groups were assessed together (r = 0.538, p = 0.003**)        
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Table I: Gender distribution in the study population (n = 75) 
 
Group n = 75            Male                       Female 
      n %       Age 
Mean ± S.D
    n %         Age 
Mean ± S.D
Group I 25 8 32 57.57 ± 12.69 17 68 50.72 ± 7.47 
Group II 25 14 56 58.57 ± 6.80 11 44 51.27 ± 10.00 
Group III 25 13 52 54.42 ± 8.15 12 48 51.67 ± 8.06 
 
 
Graph I: Gender distribution in the study population (n = 75) 
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Table II: Mean blood glucose in each group 
 
 
          Variable                      Study groups 
                      (Mean ± SD)
           p-value 
            I 
    (n=25) 
       II 
   (n=25)
       III 
    (n=25)
I & II  I & III     II & III 
Random blood 
glucose in 
mg/dl 
87.08 ± 
18.07 
257.44 ± 
54.47 
79.86 ± 
17.05 
0.000**   0.742     0.000** 
 
                             
                            Controlled blood glucose    : 120-200mg/dl    
                            Uncontrolled blood glucose:  >200mg/dl 
                            Normal blood glucose          :  80 -120mg/dl 
  
Graph II: Mean blood glucose in each group (n=75) 
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Table III: Mean HbA1C values in each group 
 
          Variable                      Study groups 
                      (Mean ± SD)
           p-value 
            I 
    (n=25) 
       II 
   (n=25)
       III 
    (n=25)
I & II  I & III     II & III 
     HbA1C in % 6.7 ± 1.4 8.6 ± 1.8 4.9 ± 0.80 0.000**  0.000**     0.000** 
 
 
                      Normal HbA1C: 5 - 8% 
 
 
Graph III: Mean HbA1C values in the study groups (n=75) 
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Table IV: Mean salivary glucose values in each group 
 
 
          Variable                      Study groups 
                      (Mean ± SD)
           p-value 
            I 
    (n=25) 
       II 
   (n=25)
       III 
    (n=25)
I & II  I & III     II & III 
Salivary 
glucose in 
mg/dl 
9.7 ± 7.6 12.1 ± 9.6 8.6 ± 7.5 0.357  0.927     0.356 
 
 
 
 
Graph IV: Mean salivary glucose values in each group (n=75) 
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Table V: Mean salivary AGE values in each groups 
 
 
          Variable                      Study groups 
                      (Mean ± SD)
                  p-value 
            I 
    (n=25) 
       II 
   (n=25)
       III 
    (n=25)
I & II  I & III     II & III 
Salivary AGE 
in ppm 
3.5 ± 1.2 6.3 ± 2.11 1.99 ± 0.80 0.000**  0.180     0.000** 
 
Graph V: Mean salivary AGE values in each groups (n =38) 
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Table VI: Pearson’s correlation analysis of blood glucose and HbA1C in the study    
groups                     
              Groups Correlation coefficient (r)          p- value   
   Group I  (controlled)        -0.546            0 .005**   
   Group II (uncontrolled)         0.242          0 .243  
   Group III(non diabetic)         0 .113           0 .591 
   Groups I, II, III         0 .620       0 .000** 
Graph VIa: Pearson’s correlation analysis of blood glucose and HbA1C in     
                    group I(controlled) n=25 
 
Graph VIb: Pearson’s correlation analysis of blood glucose and HbA1C in    
                    Group II (uncontrolled) n=25 
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Graph VIc: Pearson’s correlation analysis of blood glucose and HbA1C in    
                    Group III (non diabetic) n=25 
 
 
 
 
Graph VId: Pearson’s correlation analysis of blood glucose and HbA1C in    
                    all the groups (n=75) 
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Table VII: Pearson’s correlation analysis of blood glucose and salivary glucose  
                   in the study groups 
 
              Groups Correlation coefficient (r)          p- value   
   Group I  (controlled)         -0.119      0.572     
   Group II (uncontrolled)          0.351      0.086 
   Group III(non diabetic)         -0.414      0.040* 
   Group I,II,III          0.199      0.086 
Graph VIIa: Pearson’s correlation analysis of blood glucose and salivary  
                      glucose in group I(controlled) n=25 
 
Graph VIIb: Pearson’s correlation analysis of blood glucose and salivary  
                      glucose in group II(uncontrolled) n=25 
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Graph VIIc: Pearson’s correlation analysis of blood glucose and salivary  
                      glucose in group III (non diabetic) n=25 
 
 
Graph VIId: Pearson’s correlation analysis of blood glucose and salivary glucose in    
                    all the groups (n=75) 
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Table VIII: Pearson’s correlation analysis of salivary glucose and salivary  
                   AGE in the study   groups 
              Groups Correlation coefficient (r)          p- value   
   Group I  (controlled)             -0.083         0 .799 
   Group II (uncontrolled)              0.134         0 .573 
   Group III(non diabetic)              0.291         0 .576 
   Group I,II,III            -0.380         0 .019 
Graph VIIIa: Pearson’s correlation analysis of salivary glucose and salivary  
                         AGE in group I (controlled) n=20 
 
Graph VIIIb: Pearson’s correlation analysis of salivary glucose and salivary  
                   AGE in group II (uncontrolled) n=12 
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Graph VIIIc: Pearson’s correlation analysis of salivary glucose and salivary AGE in     
                     group III (non diabetic) n= 6 
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Graph VIIId: Pearson’s correlation analysis of salivary glucose and salivary AGE in   
                         all the groups n = 38 
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Table IX: Pearson’s correlation analysis of salivary AGE and HbA1C in the study 
groups  
 
              Groups Correlation coefficient (r)          p- value   
   Group I  (controlled)           -0.100           0.758 
   Group II (uncontrolled)            0 .095           0.692 
   Group III(non diabetic)            0 .433           0.391 
   Group I,II,III           -0.419           0.009** 
Graph IXa: Pearson’s correlation analysis of salivary AGE and HbA1C in     
                  group I (controlled) n=20 
 
Graph IXb: Pearson’s correlation analysis of salivary AGE and HbA1C in     
                 group II (uncontrolled) n=12 
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Graph IXc: Pearson’s correlation analysis of salivary AGE and HbA1C in     
                 Group III (non diabetic) n=6 
 
 
 
Graph IXd: Pearson’s correlation analysis of salivary AGE and HbA1C between all  
                     the groups n = 38     
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Table X: Pearson’s correlation analysis of random blood glucose and salivary AGE  
                levels in the study groups  
 
              Groups Correlation coefficient (r)          p- value   
   Group I  (controlled)           0.199          0.556 
   Group II (uncontrolled)           0.126         0.598 
   Group III(non diabetic)          -0.852         0 .031* 
   Group I,II,III          -0.369         0.022* 
 
Graph Xa: Pearson’s correlation analysis of random blood glucose and salivary  
                   AGE in Group I(controlled diabetes) n = 20 
 
Graph Xb: Pearson’s correlation analysis of random blood glucose and salivary  
                    AGE in Group II(uncontrolled diabetes) n = 12 
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Graph Xc: Pearson’s correlation analysis of random blood glucose and salivary  
                   AGE in Group III (Non diabetic) n = 6 
 
 
Graph Xd: Pearson’s correlation analysis of random blood glucose and salivary  
                    AGE between all the groups (n = 38)  
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Table XI: Pearson’s correlation analysis of salivary glucose and periodontal status  
                 in the study groups(n = 75) 
 
 
 
              Groups Correlation coefficient (r)          p- value   
        Group I,II,III         0 .245         0 .034* 
 
 
Graph XI: Pearson’s correlation analysis of salivary glucose and periodontal status  
                   in the study groups (n = 75) 
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Table XII: Pearson’s correlation analysis of salivary AGE and periodontal status  
                   in the study groups(n = 38) 
 
 
              Groups Correlation coefficient (r)          p- value   
        Group I,II,III            0 .538          0.003** 
 
 
 
Graph XII: Pearson’s correlation analysis of salivary AGE and periodontal status  
                     In the study groups (n = 38) 
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            Diabetic patients are prone to develop increased Advanced Glycation End 
Products (AGE) which are irreversible products of non-enzymatic glycation and 
oxidation of proteins causing local complications, overall morbidity and mortality. The 
presence of advanced glycation endproducts in patients with diabetes mellitus was 
associated with increased periodontal damage as proposed by Zidek et al (2003) 6. 
      The present study population comprised of 75 patients, 25 each in group. Group I - 
controlled, Group II - uncontrolled and Group III - non-diabetic. Of the 75 patients, 35 
were males and 40 were females. The number of females were higher compared to males 
in our study. This could be due to the fact that females tend to seek treatment early and 
also one of the exclusion criteria in our study was smoking. Although the mean age of 
patients with uncontrolled diabetes (group II) was higher than that in controlled diabetes 
(group I) the difference was statistically insignificant. 
       Although the mean random blood glucose levels showed difference between the 
three groups (Group II > Group I > Group III), the difference was statistically significant 
only between group I and II (p = 0.000**) and between group II and III (p = 0.000**). 
This was consistent with the findings reported by Ichiro et al (2003) 25       
       In our study mean HbA1C levels were higher in diabetics than in non-diabetics 
(Group II > Group I > Group III). This difference was statistically significant when 
compared between any of the two groups (p = 0.000**). This was consistent with the 
findings of Dodds et al (2000)52 who showed a statistically significant difference in 
HbA1C levels between diabetic and non diabetic patients. 
        Although salivary glucose levels were higher in diabetics than in non-diabetics 
(Group II > Group I > Group III) the difference was not statistically significant when 
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compared between any of the two groups. [Group I & II (p = 0.357), group I & III (p = 
0.927), group II & III (p = 0.356)]. This is similar to findings reported by Aryeh et al 
(1998)53 where in salivary composition like salivary glucose, potassium and total protein 
were elevated in diabetic patients compared to non diabetic. Also, Reuterving et al 
(1987)54 have shown that except for salivary glucose the other composition in saliva did 
not show any difference between diabetic ad non diabetic patients.  
       The salivary AGE levels were higher in diabetics than in non – diabetics (Group II > 
Group I > Group III). This difference was statistically significant when compared 
between group I and II, group II and III (p = 0.000**).Group I and II and between group 
II and III (p = 0.000**).This is consistent with the findings reported by Zidek et al 
(2004)6 who worked on 52 diabetic and 47 non diabetic patients showing significant 
difference in salivary AGE level between diabetic and non diabetic patients 
        HbA1C concentration increased significantly with increase in random blood glucose 
levels (r = 0.620, p = 0.000**) in the study groups. The concentration of HbA1C is an 
indicator of average blood glucose concentration for the preceding 2-3 months. Our 
results are consistent with Nathan et al (2008)55 who worked on 268 diabetic and 80 
nondiabetic patients. Also in our study there was significant negative correlation in 
controlled diabetes (r = -0.546, p = 0.005). This is due to the fact that HbA1C value is 
unaffected by insulin, diet and exercise, the value remains the same till the life of an red 
blood cells and unaffected by short term fluctuation in blood glucose levels. 
       In group II (r = 0.351, p = 0.086) there was an increase in salivary glucose levels 
with increase in random blood glucose levels. This positive correlation was also observed 
when all the study groups were assessed together(r = 0.199, p = 0.086). While in group I 
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as the random blood glucose levels increases the salivary glucose level decreased. There 
was negative correlation in group I (r = -0.119, p = 0.572) and III (r = -0.414, p = 0.040*) 
Several factors may account for the varying observed correlation between blood and 
salivary glucose concentrations. They include oral retention of alimentary carbohydrates, 
glucose utilization by oral bacteria, release of carbohydrates from salivary glycoproteins, 
and contamination of saliva by a large outflow of crevicular fluid in patients with a poor 
gingival status. The negative correlation in group I and III is consistent with the findings 
reported by Reuterving et al (1987)54 who observed  that salivary glucose levels was low 
during the period of better metabolic control, therefore in well controlled individuals with 
altered glucose metabolism there was lower salivary glucose levels. Also, the observed 
correlation is consistent with the findings of Amer et al (2001)56 who reported that 
salivary glucose increases as serum glucose increases, while the salivary samples from 
age matched non-diabetic did not show any correlation  
       We observed that the salivary AGE concentration significantly decreased as the 
levels of salivary glucose increased and this negative correlation was statistically 
significant (r = -0.380, p = 0.019*).The salivary glucose is affected by bacteria and 
enzymes in the mouth. The microorganism utilizes the glucose rapidly so it is difficult to 
measure it without ultra- filtration. Salivary AGE is not formed from salivary glucose. 
Reports have suggested that the increased glucose formed in the serum can be elicited in 
the gingival crevicular fluid and this glucose is utilized in the formation of salivary AGE. 
Beikler et al  (2002)28 who worked on 32 non-diabetic and 13 diabetic patients with 
moderate to severe periodontitis found that blood oozing during routine periodontal 
examination may be used for diabetes mellitus screening in a dental office setting. 
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Khader  et al (2006) 29 in his study compared gingival crevicular blood sample and  r 
sample obtained by finger puncture using a self-monitoring device and found that there 
was correlation, there by stating that Gingival crevicular blood can provide an acceptable 
source for measuring blood glucose level.  
         When all the groups were assessed together, as the values of HbA1C increases the 
levels of AGE in saliva decreased significantly (r = - 0.419, p = 0.009). Our results are 
consistent with the results of Ichiro et al (2003)25. HbA1c in erythrocytes cannot be 
measured with saliva. 
       The salivary AGE levels increased when there was an increase in blood glucose 
levels in both group I and II. However this positive correlation was not statistically 
significant in Group I (r = 0.199, p = 0.556) and in group II (r =0.126, p = 0.598). Our 
results are consistent with the results of Zidek et al (2004) 6 who reported that NMR 
signal was more in diabetics compared to that in non – diabetic patients. 
      There was a significant association between periodontal status and salivary glucose 
levels. As the levels of salivary glucose increased the periodontal status deteriorated 
 (r = 0.245, p = 0.034*). Tenovvuo et al (1986)56 reported that increased exposure of 
bacteria as a consequence of elevated salivary glucose was seen in controlled and 
uncontrolled diabetic. The salivary glucose increased the substrate for bacteria and 
altered plaque micro-flora favoring periodontal diseases. Oates et al (2002)57 stated that 
high circulating levels of glucose inhibit peripheral leukocyte chemotaxis and provide a 
nutrient-rich environment for bacterial or fungal replication. Kaisa et al (2000) 58 
reported that in diabetics, there is a decreased salivary flow rate and an increase in 
salivary glucose levels. Higher salivary microbial counts, especially yeast counts, are 
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related to the low salivary flow rates and high salivary glucose levels which contribute to 
periodontitis. 
            There was a significant association between periodontal status and salivary AGE 
levels  (r = 0.538, p = 0.003**). However, given the limited sample size in this subgroup 
(n=38) and other confounding factors (age, gender, regular oral hygiene maintenance, 
early diagnosis, use of other substances, maintenance of diabetic status, food habits and 
genetic status). We state the above results confirm an association between diabetes 
mellitus and periodontitis but a cause and effect relationship has to be established taking 
into account the confounding factors. AGE is responsible for various changes leading to 
collagen crosslinking, and basement membrane disintegration. AGE can also bind to 
macrophage receptors and induce cytokin (IL- 1 & TNF-α) up-regulation. This in turn 
induces alteration in the matrix metalloproteinase 8 (MMP 8) periodontal tissue of 
diabetics 60. Killi M et al (2002)61 showed that MMP type 8 originates from 
polymorphonuclear (PMN) leukocyte, epithelial cells and plasma cells and is detected in 
the gingival cervicular fluid of inflamed periodontium. Villela B et al (1987)62 reported 
that there was correlation between GCF collagenase and pocket depth.             
           Brown et al (1998)63 reported that one of the major complications of 
hyperglycemia is alteration of circulating proteins. These proteins when exposed to 
aldose sugar undergo non-enzymatic glycation and oxidation resulting in AGE formation. 
Valssara et al (1992)64 reported that AGE act on target cells via their binding to cell 
surface polypeptide receptor, the binding being the immunoglobulin superfamily called 
the Receptor for AGE (RAGE). AGE can interact with RAGE on cells such as 
macrophages, endothelial cells and fibroblast which stimulate the production of MMP. 
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Neutrophils release diacyl glycerol, protein kinase C and superoxide which also stimulate 
MMP. Schmidt et al (2009) 65 reported that AGE in the gingival of the diabetics was 
associated with oxidative stress a potential mechanism of accelerated tissue injury. 
Wolowczuk et al (2008)66showed that binding of AGE to their receptor RAGE initiates 
cellular signals that activate NF-kappaB, which results in transcription of 
proinflammatory factors causing chronic inflammatory diseases.  
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            Diabetic patients are prone to develop increased Advanced Glycation End 
Products (AGE) which are irreversible products of non-enzymatic glycation and 
oxidation of proteins causing local complications, overall morbidity and mortality. The 
presence of advanced glycation endproducts in patients with diabetes mellitus was 
associated with increased periodontal damage as proposed by Zidek et al (2003) 6.
      The present study population comprised of 75 patients, 25 each in group. Group I - 
controlled, Group II - uncontrolled and Group III - non-diabetic. Of the 75 patients, 35 
were males and 40 were females. The number of females were higher compared to males 
in our study. This could be due to the fact that females tend to seek treatment early and 
also one of the exclusion criteria in our study was smoking. Although the mean age of 
patients with uncontrolled diabetes (group II) was higher than that in controlled diabetes 
(group I) the difference was statistically insignificant. 
       Although the mean random blood glucose levels showed difference between the 
three groups (Group II > Group I > Group III), the difference was statistically significant 
only between group I and II (p = 0.000**) and between group II and III (p = 0.000**). 
This was consistent with the findings reported by Ichiro et al (2003) 25
       In our study mean HbA1C levels were higher in diabetics than in non-diabetics 
(Group II > Group I > Group III). This difference was statistically significant when 
compared between any of the two groups (p = 0.000**). This was consistent with the 
findings of Dodds et al (2000)52 who showed a statistically significant difference in 
HbA1C levels between diabetic and non diabetic patients. 
        Although salivary glucose levels were higher in diabetics than in non-diabetics 
(Group II > Group I > Group III) the difference was not statistically significant when 
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compared between any of the two groups. [Group I & II (p = 0.357), group I & III (p = 
0.927), group II & III (p = 0.356)]. This is similar to findings reported by Aryeh et al 
(1998)53 where in salivary composition like salivary glucose, potassium and total protein 
were elevated in diabetic patients compared to non diabetic. Also, Reuterving et al
(1987)54 have shown that except for salivary glucose the other composition in saliva did 
not show any difference between diabetic ad non diabetic patients.
       The salivary AGE levels were higher in diabetics than in non – diabetics (Group II > 
Group I > Group III). This difference was statistically significant when compared 
between group I and II, group II and III (p = 0.000**).Group I and II and between group 
II and III (p = 0.000**).This is consistent with the findings reported by Zidek et al
(2004)6 who worked on 52 diabetic and 47 non diabetic patients showing significant 
difference in salivary AGE level between diabetic and non diabetic patients 
        HbA1C concentration increased significantly with increase in random blood glucose 
levels (r = 0.620, p = 0.000**) in the study groups. The concentration of HbA1C is an 
indicator of average blood glucose concentration for the preceding 2-3 months. Our 
results are consistent with Nathan et al (2008)55 who worked on 268 diabetic and 80 
nondiabetic patients. Also in our study there was significant negative correlation in 
controlled diabetes (r = -0.546, p = 0.005). This is due to the fact that HbA1C value is 
unaffected by insulin, diet and exercise, the value remains the same till the life of an red 
blood cells and unaffected by short term fluctuation in blood glucose levels. 
       In group II (r = 0.351, p = 0.086) there was an increase in salivary glucose levels 
with increase in random blood glucose levels. This positive correlation was also observed 
when all the study groups were assessed together(r = 0.199, p = 0.086). While in group I 
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as the random blood glucose levels increases the salivary glucose level decreased. There 
was negative correlation in group I (r = -0.119, p = 0.572) and III (r = -0.414, p = 0.040*) 
Several factors may account for the varying observed correlation between blood and 
salivary glucose concentrations. They include oral retention of alimentary carbohydrates, 
glucose utilization by oral bacteria, release of carbohydrates from salivary glycoproteins, 
and contamination of saliva by a large outflow of crevicular fluid in patients with a poor 
gingival status. The negative correlation in group I and III is consistent with the findings 
reported by Reuterving et al (1987)54 who observed  that salivary glucose levels was low 
during the period of better metabolic control, therefore in well controlled individuals with 
altered glucose metabolism there was lower salivary glucose levels. Also, the observed 
correlation is consistent with the findings of Amer et al (2001)56 who reported that 
salivary glucose increases as serum glucose increases, while the salivary samples from 
age matched non-diabetic did not show any correlation
       We observed that the salivary AGE concentration significantly decreased as the 
levels of salivary glucose increased and this negative correlation was statistically 
significant (r = -0.380, p = 0.019*).The salivary glucose is affected by bacteria and 
enzymes in the mouth. The microorganism utilizes the glucose rapidly so it is difficult to 
measure it without ultra- filtration. Salivary AGE is not formed from salivary glucose. 
Reports have suggested that the increased glucose formed in the serum can be elicited in 
the gingival crevicular fluid and this glucose is utilized in the formation of salivary AGE. 
Beikler et al (2002)28 who worked on 32 non-diabetic and 13 diabetic patients with 
moderate to severe periodontitis found that blood oozing during routine periodontal 
examination may be used for diabetes mellitus screening in a dental office setting. 
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Khader  et al (2006) 29 in his study compared gingival crevicular blood sample and  r 
sample obtained by finger puncture using a self-monitoring device and found that there 
was correlation, there by stating that Gingival crevicular blood can provide an acceptable 
source for measuring blood glucose level.
         When all the groups were assessed together, as the values of HbA1C increases the 
levels of AGE in saliva decreased significantly (r = - 0.419, p = 0.009). Our results are 
consistent with the results of Ichiro et al (2003)25. HbA1c in erythrocytes cannot be 
measured with saliva.
       The salivary AGE levels increased when there was an increase in blood glucose 
levels in both group I and II. However this positive correlation was not statistically 
significant in Group I (r = 0.199, p = 0.556) and in group II (r =0.126, p = 0.598). Our 
results are consistent with the results of Zidek et al (2004) 6 who reported that NMR 
signal was more in diabetics compared to that in non – diabetic patients. 
  There was a significant association between periodontal status and salivary glucose 
levels. As the levels of salivary glucose increased the periodontal status deteriorated 
 (r = 0.245, p = 0.034*). Tenovvuo et al (1986)56 reported that increased exposure of 
bacteria as a consequence of elevated salivary glucose was seen in controlled and 
uncontrolled diabetic. The salivary glucose increased the substrate for bacteria and 
altered plaque micro-flora favoring periodontal diseases. Oates et al (2002)57 stated that 
high circulating levels of glucose inhibit peripheral leukocyte chemotaxis and provide a 
nutrient-rich environment for bacterial or fungal replication. Kaisa et al (2000) 58
reported that in diabetics, there is a decreased salivary flow rate and an increase in 
salivary glucose levels. Higher salivary microbial counts, especially yeast counts, are 
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related to the low salivary flow rates and high salivary glucose levels which contribute to 
periodontitis.
            There was a significant association between periodontal status and salivary AGE 
levels  (r = 0.538, p = 0.003**). However, given the limited sample size in this subgroup 
(n=38) and other confounding factors (age, gender, regular oral hygiene maintenance, 
early diagnosis, use of other substances, maintenance of diabetic status, food habits and 
genetic status). We state the above results confirm an association between diabetes 
mellitus and periodontitis but a cause and effect relationship has to be established taking 
into account the confounding factors. AGE is responsible for various changes leading to 
collagen crosslinking, and basement membrane disintegration. AGE can also bind to 
macrophage receptors and induce cytokin (IL- 1 & TNF-Į) up-regulation. This in turn 
induces alteration in the matrix metalloproteinase 8 (MMP 8) periodontal tissue of 
diabetics 60. Killi M et al (2002)61 showed that MMP type 8 originates from 
polymorphonuclear (PMN) leukocyte, epithelial cells and plasma cells and is detected in 
the gingival cervicular fluid of inflamed periodontium. Villela B et al (1987)62 reported 
that there was correlation between GCF collagenase and pocket depth.
Brown et al (1998)63 reported that one of the major complications of 
hyperglycemia is alteration of circulating proteins. These proteins when exposed to 
aldose sugar undergo non-enzymatic glycation and oxidation resulting in AGE formation. 
Valssara et al (1992)64 reported that AGE act on target cells via their binding to cell 
surface polypeptide receptor, the binding being the immunoglobulin superfamily called 
the Receptor for AGE (RAGE). AGE can interact with RAGE on cells such as 
macrophages, endothelial cells and fibroblast which stimulate the production of MMP. 
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Neutrophils release diacyl glycerol, protein kinase C and superoxide which also stimulate 
MMP. Schmidt et al (2009) 65 reported that AGE in the gingival of the diabetics was 
associated with oxidative stress a potential mechanism of accelerated tissue injury.
Wolowczuk et al (2008)66showed that binding of AGE to their receptor RAGE initiates 
cellular signals that activate NF-kappaB, which results in transcription of 
proinflammatory factors causing chronic inflammatory diseases.
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                                                        Annexure 1 
 
 
 
 
 
 
 
                                                            Annexure 2 
CONVERSION CHART OF GLYCOSYLATED HEMOGLOBIN A1% TO MEAN 
        BLOOD GLUCOSE AND GLYCOSYLATED HEMOGLOBIN A1C % 
A1                       A1c                     MBH                         A1              A1c               MBH   
6.0                       4.30                       35                             7.9               5.88              105       
6.1                       4.38                       39                              8.0              5.97              109 
6.2                       4.46                       43                              8.1              6.05              112      
6.3                       4.54                       46                               8.2             6.14              116 
6.4                       4.63                       50                               8.3              6.22             120       
6.5                       4.71                       54                              8.4              6.30              123 
6.6                       4.79                       58                              8.5              6.39              127 
6.7                       4.88                       61                              8.6              6.47              131 
6.8                       4.96                       65                              8.7              6.55              134 
6.9                       5.05                       68                              8.8              6.64              138 
7.0                       5.13                       72                              8.9              6.72              142 
7.1                       5.21                       76                              9.0              6.81              145 
7.2                      5.30                        79                              9.1              6.89              149 
7.3                      5.38                        83                              9.2              6.97              153 
7.4                      5.46                        87                              9.3              7.06              156 
7.5                      5.55                        90                              9.4               7.14             160 
7.6                      5.63                        94                              9.5              7.22              164 
7.7                      5.72                        98                              9.6              7.31              167 
7.8                      5.80                        101                            9.7              7.39              171 
 
 A1                       A1c                     MBH                          A1              A1c               MBH       
9.8                      7.48                      175                             12.1            9.40                259 
9.9                      7.56                      178                             12.2            9.49                263 
10.1                    7.64                      186                             12.3            9.57                266 
10.2                    7.73                      189                             12.4            9.65                270 
10.3                    7.81                      193                             12.5            9.74                 274 
10.4                    7.89                      197                             12.6            9.82                 277 
10.5                    7.98                      200                              12.7          9.99                  285 
10.6                     8.06                     204                             12.8           10.07                288 
10.7                    8.15                       207                            12.9           10.16                292 
10.8                    8.23                       211                             13.0           10.24                295 
10.9                    8.31                       215                             13.1           10.33                299 
11.0                    8.40                       219                             13.2           10.41                304 
11.1                    8.48                       222                             13.3           10.49                309 
11.2                    8.56                      226                              13.4           10.58                314 
11.3                    8.65                      230                               13.5          10.66               320 
11.4                    8.73                      233                               13.6          10.74               326 
11.5                    8.82                      237 
11.6                    8.90                       241 
11.7                    8.98                       244 
11.8                    9.07                       248 
11.9                    9.15                       252 
12.0                   9.24                        255 
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                                  LIST OF ABBREVATIONS  
 
 
            DM                     -          Diabetes mellitus 
            AGEs                 -          Advanced glycation end products  
            FPG                   -           Fasting blood glucose 
            PG                      -          Postprandial glucose 
            OGTT                -          Oral glucose tolerance test 
            HbA1C               -          Glycosylated hemoglobin 
            THb                   -           Total hemoglobin fraction 
            GOD                  -           Glucose oxidase 
            POD                   -           Perioxidase 
            NMR                  -           Nuclear magnetic resonance spectroscopy 
            CPITN              -           Community periodontal index for  
                                                    treatment needs 
           MMP                  -           Matrix metalloproteinase  
           RAGE                  -          Receptor for advanced glycation end  
                                                    product 
              
  
